According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has ... which was conducted in patients with uncontrolled CSU who were on standard-of-care antihistamines. Study C, the second LIBERTY ...

Sanofi and Regeneron’s checkpoint ... much to be done to improve therapy. According to Regeneron, there is no approved standard of care after first-line chemotherapy in advanced cervical cancer.

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

NICE has said “no” to regular NHS funding for Sanofi and Regeneron’s Dupixent (dupilumab ... compared with standard care. According to NICE the most relevant use for Dupixent in asthma ...

Sanofi said on Thursday it would ... 2025 Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals , Illumina and 17 U.S. health systems will take a $320 million stake ...

DUPIXENT sales contribute to Regeneron's revenue as royalties that are recorded by Sanofi (SNY). Regeneron's profit share under the agreement with Sanofi is 28% and revenue from the product for Q3 ...